CA2302438A1

CA2302438A1 - Composes d'heteroarylcarboxamide actifs contre les etats pathologiques lies aux proteine tyrosine kinases

Composes d'heteroarylcarboxamide actifs contre les etats pathologiques lies aux proteine tyrosine kinases Download PDF

Info

Publication number: CA2302438A1
Authority: CA; Canada
Prior art keywords: cancer; compound; group; cells; salt
Prior art date: 1997-05-19
Legal status : Abandoned

Application number

CA002302438A

Other languages

English (en)

Inventor

Gerald Mcmahon

Peng Cho Tang

Laura Kay Shawver

Klaus Peter Hirth

Current Assignee

Sugen LLC

Original Assignee

Individual

Priority date

1997-05-19

Filing date

1998-05-18

Publication date

1998-11-26

1998-05-18 Application filed by Individual filed Critical Individual

1998-11-26 Publication of CA2302438A1 publication Critical patent/CA2302438A1/fr

Status Abandoned legal-status Critical Current

Links

102000004022 Protein-Tyrosine Kinases Human genes 0.000 title claims abstract description 16
108090000412 Protein-Tyrosine Kinases Proteins 0.000 title claims abstract description 16
150000001875 compounds Chemical class 0.000 title claims description 192
206010028980 Neoplasm Diseases 0.000 claims abstract description 217
230000000694 effects Effects 0.000 claims abstract description 166
238000000034 method Methods 0.000 claims abstract description 154
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 133
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims abstract description 114
108091008794 FGF receptors Proteins 0.000 claims abstract description 111
238000011282 treatment Methods 0.000 claims abstract description 75
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims abstract description 46
208000005017 glioblastoma Diseases 0.000 claims abstract description 24
206010003571 Astrocytoma Diseases 0.000 claims abstract description 13
OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims abstract description 10
210000004027 cell Anatomy 0.000 claims description 302
208000035475 disorder Diseases 0.000 claims description 118
201000011510 cancer Diseases 0.000 claims description 98
-1 heteroalicyclic Chemical group 0.000 claims description 57
108091008606 PDGF receptors Proteins 0.000 claims description 52
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims description 46
150000003839 salts Chemical class 0.000 claims description 41
239000001257 hydrogen Substances 0.000 claims description 39
229910052739 hydrogen Inorganic materials 0.000 claims description 39
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 38
125000000217 alkyl group Chemical group 0.000 claims description 38
241000282414 Homo sapiens Species 0.000 claims description 36
102000027426 receptor tyrosine kinases Human genes 0.000 claims description 36
108091008598 receptor tyrosine kinases Proteins 0.000 claims description 36
206010027476 Metastases Diseases 0.000 claims description 34
208000003174 Brain Neoplasms Diseases 0.000 claims description 32
230000009401 metastasis Effects 0.000 claims description 30
125000000753 cycloalkyl group Chemical group 0.000 claims description 29
230000002401 inhibitory effect Effects 0.000 claims description 29
125000003118 aryl group Chemical group 0.000 claims description 28
125000001072 heteroaryl group Chemical group 0.000 claims description 26
150000002431 hydrogen Chemical group 0.000 claims description 26
229910052757 nitrogen Inorganic materials 0.000 claims description 23
230000002062 proliferating effect Effects 0.000 claims description 22
239000008196 pharmacological composition Substances 0.000 claims description 20
238000011068 loading method Methods 0.000 claims description 19
125000005152 trihalomethanesulfonyl group Chemical group 0.000 claims description 18
208000026310 Breast neoplasm Diseases 0.000 claims description 17
206010006187 Breast cancer Diseases 0.000 claims description 16
238000012423 maintenance Methods 0.000 claims description 16
125000000304 alkynyl group Chemical group 0.000 claims description 15
210000004204 blood vessel Anatomy 0.000 claims description 14
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 14
230000003176 fibrotic effect Effects 0.000 claims description 14
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 14
206010061535 Ovarian neoplasm Diseases 0.000 claims description 13
125000003342 alkenyl group Chemical group 0.000 claims description 13
230000000973 chemotherapeutic effect Effects 0.000 claims description 13
239000000126 substance Substances 0.000 claims description 13
206010018338 Glioma Diseases 0.000 claims description 12
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 12
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 12
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
208000029742 colonic neoplasm Diseases 0.000 claims description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
229910052760 oxygen Inorganic materials 0.000 claims description 12
239000001301 oxygen Substances 0.000 claims description 12
229910052717 sulfur Inorganic materials 0.000 claims description 12
239000011593 sulfur Substances 0.000 claims description 12
206010033128 Ovarian cancer Diseases 0.000 claims description 11
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
206010060862 Prostate cancer Diseases 0.000 claims description 11
125000003545 alkoxy group Chemical group 0.000 claims description 11
208000008443 pancreatic carcinoma Diseases 0.000 claims description 11
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
208000007766 Kaposi sarcoma Diseases 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 10
208000020816 lung neoplasm Diseases 0.000 claims description 10
206010005003 Bladder cancer Diseases 0.000 claims description 9
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 9
208000019425 cirrhosis of liver Diseases 0.000 claims description 9
210000003734 kidney Anatomy 0.000 claims description 9
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
201000002528 pancreatic cancer Diseases 0.000 claims description 9
206010009944 Colon cancer Diseases 0.000 claims description 8
125000004104 aryloxy group Chemical group 0.000 claims description 8
125000004093 cyano group Chemical group *C#N 0.000 claims description 8
125000005553 heteroaryloxy group Chemical group 0.000 claims description 8
201000001441 melanoma Diseases 0.000 claims description 8
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
125000005190 thiohydroxy group Chemical group 0.000 claims description 8
125000005423 trihalomethanesulfonamido group Chemical group 0.000 claims description 8
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
241000124008 Mammalia Species 0.000 claims description 7
229910052799 carbon Inorganic materials 0.000 claims description 7
201000005202 lung cancer Diseases 0.000 claims description 7
125000005499 phosphonyl group Chemical group 0.000 claims description 7
201000005112 urinary bladder cancer Diseases 0.000 claims description 7
230000002265 prevention Effects 0.000 claims description 6
201000001320 Atherosclerosis Diseases 0.000 claims description 5
208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
125000004429 atom Chemical group 0.000 claims description 5
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 5
125000004953 trihalomethyl group Chemical group 0.000 claims description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
208000003445 Mouth Neoplasms Diseases 0.000 claims description 4
206010038389 Renal cancer Diseases 0.000 claims description 4
125000005631 S-sulfonamido group Chemical group 0.000 claims description 4
238000001802 infusion Methods 0.000 claims description 4
201000010982 kidney cancer Diseases 0.000 claims description 4
230000037390 scarring Effects 0.000 claims description 4
230000000381 tumorigenic effect Effects 0.000 claims description 4
208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 3
206010061934 Salivary gland cancer Diseases 0.000 claims description 3
208000034189 Sclerosis Diseases 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
125000004385 trihaloalkyl group Chemical group 0.000 claims description 3
206010051113 Arterial restenosis Diseases 0.000 claims description 2
208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
206010039710 Scleroderma Diseases 0.000 claims description 2
125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 2
201000006334 interstitial nephritis Diseases 0.000 claims description 2
102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims 4
125000001475 halogen functional group Chemical group 0.000 claims 2
206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 abstract description 106
230000002159 abnormal effect Effects 0.000 abstract description 15
229960005243 carmustine Drugs 0.000 abstract description 2
239000000243 solution Substances 0.000 description 77
239000003814 drug Substances 0.000 description 70
101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 67
102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 67
229940079593 drug Drugs 0.000 description 66
239000002953 phosphate buffered saline Substances 0.000 description 66
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 61
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 59
239000003446 ligand Substances 0.000 description 59
230000005764 inhibitory process Effects 0.000 description 48
239000000203 mixture Substances 0.000 description 46
238000002965 ELISA Methods 0.000 description 44
238000012360 testing method Methods 0.000 description 43
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
241001465754 Metazoa Species 0.000 description 39
101800003838 Epidermal growth factor Proteins 0.000 description 38
102400001368 Epidermal growth factor Human genes 0.000 description 38
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 38
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 38
229940116977 epidermal growth factor Drugs 0.000 description 38
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 38
101150021185 FGF gene Proteins 0.000 description 36
230000008569 process Effects 0.000 description 36
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 35
238000003556 assay Methods 0.000 description 33
102000005962 receptors Human genes 0.000 description 33
108020003175 receptors Proteins 0.000 description 33
108091003079 Bovine Serum Albumin Proteins 0.000 description 31
239000003153 chemical reaction reagent Substances 0.000 description 31
239000002609 medium Substances 0.000 description 30
230000014509 gene expression Effects 0.000 description 28
210000001519 tissue Anatomy 0.000 description 28
230000004614 tumor growth Effects 0.000 description 28
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 26
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 26
239000006180 TBST buffer Substances 0.000 description 25
239000012091 fetal bovine serum Substances 0.000 description 25
238000012546 transfer Methods 0.000 description 25
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
230000004663 cell proliferation Effects 0.000 description 24
238000010790 dilution Methods 0.000 description 24
239000012895 dilution Substances 0.000 description 24
230000006820 DNA synthesis Effects 0.000 description 23
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 23
239000000463 material Substances 0.000 description 23
230000000903 blocking effect Effects 0.000 description 22
230000015572 biosynthetic process Effects 0.000 description 21
230000001413 cellular effect Effects 0.000 description 21
108090000623 proteins and genes Proteins 0.000 description 21
210000002966 serum Anatomy 0.000 description 21
ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 20
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 20
235000018102 proteins Nutrition 0.000 description 20
102000004169 proteins and genes Human genes 0.000 description 20
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 19
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 19
241000699670 Mus sp. Species 0.000 description 19
229950004398 broxuridine Drugs 0.000 description 19
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 19
238000002513 implantation Methods 0.000 description 19
238000002372 labelling Methods 0.000 description 19
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
238000002474 experimental method Methods 0.000 description 18
230000035755 proliferation Effects 0.000 description 18
238000010079 rubber tapping Methods 0.000 description 18
239000002246 antineoplastic agent Substances 0.000 description 17
230000003197 catalytic effect Effects 0.000 description 17
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 17
229940127089 cytotoxic agent Drugs 0.000 description 17
235000013336 milk Nutrition 0.000 description 17
239000008267 milk Substances 0.000 description 17
210000004080 milk Anatomy 0.000 description 17
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 16
239000000872 buffer Substances 0.000 description 16
238000009472 formulation Methods 0.000 description 16
238000001727 in vivo Methods 0.000 description 16
239000003795 chemical substances by application Substances 0.000 description 15
238000006366 phosphorylation reaction Methods 0.000 description 15
230000011664 signaling Effects 0.000 description 15
210000004881 tumor cell Anatomy 0.000 description 15
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 14
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 14
230000010261 cell growth Effects 0.000 description 14
239000007924 injection Substances 0.000 description 14
238000002347 injection Methods 0.000 description 14
239000000546 pharmaceutical excipient Substances 0.000 description 14
230000026731 phosphorylation Effects 0.000 description 14
239000011780 sodium chloride Substances 0.000 description 14
230000001225 therapeutic effect Effects 0.000 description 14
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 14
229940045145 uridine Drugs 0.000 description 14
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 13
230000004913 activation Effects 0.000 description 13
238000001514 detection method Methods 0.000 description 13
238000011161 development Methods 0.000 description 13
230000018109 developmental process Effects 0.000 description 13
201000010099 disease Diseases 0.000 description 13
238000005755 formation reaction Methods 0.000 description 13
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 12
102000038455 IGF Type 1 Receptor Human genes 0.000 description 12
108010031794 IGF Type 1 Receptor Proteins 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
150000001412 amines Chemical class 0.000 description 12
210000004556 brain Anatomy 0.000 description 12
125000004432 carbon atom Chemical group C* 0.000 description 12
229960004756 ethanol Drugs 0.000 description 12
230000012010 growth Effects 0.000 description 12
230000003834 intracellular effect Effects 0.000 description 12
230000004083 survival effect Effects 0.000 description 12
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 11
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 11
238000011534 incubation Methods 0.000 description 11
239000013642 negative control Substances 0.000 description 11
230000001988 toxicity Effects 0.000 description 11
231100000419 toxicity Toxicity 0.000 description 11
239000013504 Triton X-100 Substances 0.000 description 10
229920004890 Triton X-100 Polymers 0.000 description 10
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 10
230000033115 angiogenesis Effects 0.000 description 10
239000003112 inhibitor Substances 0.000 description 10
239000006166 lysate Substances 0.000 description 10
UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 10
239000003981 vehicle Substances 0.000 description 10
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
239000003102 growth factor Substances 0.000 description 9
125000005843 halogen group Chemical group 0.000 description 9
230000001404 mediated effect Effects 0.000 description 9
210000000056 organ Anatomy 0.000 description 9
230000036470 plasma concentration Effects 0.000 description 9
239000000047 product Substances 0.000 description 9
230000004044 response Effects 0.000 description 9
238000007920 subcutaneous administration Methods 0.000 description 9
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical group NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
229940100198 alkylating agent Drugs 0.000 description 8
239000002168 alkylating agent Substances 0.000 description 8
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 8
239000012911 assay medium Substances 0.000 description 8
239000003085 diluting agent Substances 0.000 description 8
238000005516 engineering process Methods 0.000 description 8
210000004185 liver Anatomy 0.000 description 8
210000004072 lung Anatomy 0.000 description 8
239000013641 positive control Substances 0.000 description 8
239000002244 precipitate Substances 0.000 description 8
239000012679 serum free medium Substances 0.000 description 8
230000019491 signal transduction Effects 0.000 description 8
239000007787 solid Substances 0.000 description 8
235000002374 tyrosine Nutrition 0.000 description 8
241000283707 Capra Species 0.000 description 7
102000001301 EGF receptor Human genes 0.000 description 7
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 7
238000002835 absorbance Methods 0.000 description 7
230000009471 action Effects 0.000 description 7
238000010171 animal model Methods 0.000 description 7
230000008512 biological response Effects 0.000 description 7
230000024245 cell differentiation Effects 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
230000001419 dependent effect Effects 0.000 description 7
210000002889 endothelial cell Anatomy 0.000 description 7
230000002209 hydrophobic effect Effects 0.000 description 7
230000009545 invasion Effects 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
239000002207 metabolite Substances 0.000 description 7
206010061289 metastatic neoplasm Diseases 0.000 description 7
239000000758 substrate Substances 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
238000003828 vacuum filtration Methods 0.000 description 7
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
108091007045 Cullin Ring E3 Ligases Proteins 0.000 description 6
102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 6
108010010803 Gelatin Proteins 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
108700020796 Oncogene Proteins 0.000 description 6
108091000080 Phosphotransferase Proteins 0.000 description 6
229920002472 Starch Polymers 0.000 description 6
239000002253 acid Substances 0.000 description 6
230000008901 benefit Effects 0.000 description 6
210000000481 breast Anatomy 0.000 description 6
208000035269 cancer or benign tumor Diseases 0.000 description 6
239000000969 carrier Substances 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
238000000576 coating method Methods 0.000 description 6
210000001072 colon Anatomy 0.000 description 6
231100000433 cytotoxic Toxicity 0.000 description 6
230000001472 cytotoxic effect Effects 0.000 description 6
230000009977 dual effect Effects 0.000 description 6
210000002744 extracellular matrix Anatomy 0.000 description 6
230000006870 function Effects 0.000 description 6
239000008273 gelatin Substances 0.000 description 6
229920000159 gelatin Polymers 0.000 description 6
235000019322 gelatine Nutrition 0.000 description 6
235000011852 gelatine desserts Nutrition 0.000 description 6
235000003642 hunger Nutrition 0.000 description 6
229940127121 immunoconjugate Drugs 0.000 description 6
229940126619 mouse monoclonal antibody Drugs 0.000 description 6
MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 6
230000002018 overexpression Effects 0.000 description 6
102000013415 peroxidase activity proteins Human genes 0.000 description 6
108040007629 peroxidase activity proteins Proteins 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
102000020233 phosphotransferase Human genes 0.000 description 6
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 6
239000000843 powder Substances 0.000 description 6
230000037351 starvation Effects 0.000 description 6
125000005309 thioalkoxy group Chemical group 0.000 description 6
125000005296 thioaryloxy group Chemical group 0.000 description 6
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 6
125000005404 thioheteroaryloxy group Chemical group 0.000 description 6
GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 6
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
GTSMPCBIUVYFCK-UHFFFAOYSA-N 2-(ethoxymethylidene)-3-oxo-n-[4-(trifluoromethyl)phenyl]butanamide Chemical compound CCOC=C(C(C)=O)C(=O)NC1=CC=C(C(F)(F)F)C=C1 GTSMPCBIUVYFCK-UHFFFAOYSA-N 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
SNUBGILHVSSQAY-UHFFFAOYSA-N 3-methyl-n-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide Chemical compound CC1=NOC=C1C(=O)NC1=CC=C(C(F)(F)F)C=C1 SNUBGILHVSSQAY-UHFFFAOYSA-N 0.000 description 5
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 5
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 5
102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 5
108060006698 EGF receptor Proteins 0.000 description 5
101150029707 ERBB2 gene Proteins 0.000 description 5
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 5
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 5
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 5
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 5
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 5
102000001253 Protein Kinase Human genes 0.000 description 5
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 5
206010039491 Sarcoma Diseases 0.000 description 5
238000000692 Student's t-test Methods 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000002491 angiogenic effect Effects 0.000 description 5
230000003305 autocrine Effects 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
238000002512 chemotherapy Methods 0.000 description 5
229960004397 cyclophosphamide Drugs 0.000 description 5
239000000824 cytostatic agent Chemical group 0.000 description 5
230000001085 cytostatic effect Effects 0.000 description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
FMVJYQGSRWVMQV-UHFFFAOYSA-N ethyl propiolate Chemical compound CCOC(=O)C#C FMVJYQGSRWVMQV-UHFFFAOYSA-N 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
239000002502 liposome Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
210000003584 mesangial cell Anatomy 0.000 description 5
230000001394 metastastic effect Effects 0.000 description 5
230000035772 mutation Effects 0.000 description 5
230000009826 neoplastic cell growth Effects 0.000 description 5
238000010899 nucleation Methods 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
108060006633 protein kinase Proteins 0.000 description 5
210000003491 skin Anatomy 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
235000000346 sugar Nutrition 0.000 description 5
230000009885 systemic effect Effects 0.000 description 5
231100001274 therapeutic index Toxicity 0.000 description 5
230000029663 wound healing Effects 0.000 description 5
201000009030 Carcinoma Diseases 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
201000010915 Glioblastoma multiforme Diseases 0.000 description 4
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
239000007995 HEPES buffer Substances 0.000 description 4
102000003746 Insulin Receptor Human genes 0.000 description 4
108010001127 Insulin Receptor Proteins 0.000 description 4
102100037852 Insulin-like growth factor I Human genes 0.000 description 4
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
229930182816 L-glutamine Natural products 0.000 description 4
101000851196 Mus musculus Pro-epidermal growth factor Proteins 0.000 description 4
241000204031 Mycoplasma Species 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 4
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
206010052428 Wound Diseases 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
230000003187 abdominal effect Effects 0.000 description 4
239000012298 atmosphere Substances 0.000 description 4
239000012888 bovine serum Substances 0.000 description 4
239000006143 cell culture medium Substances 0.000 description 4
239000013592 cell lysate Substances 0.000 description 4
230000033077 cellular process Effects 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
229960004316 cisplatin Drugs 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
235000021186 dishes Nutrition 0.000 description 4
238000010494 dissociation reaction Methods 0.000 description 4
230000005593 dissociations Effects 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
229960005420 etoposide Drugs 0.000 description 4
230000002440 hepatic effect Effects 0.000 description 4
208000032839 leukemia Diseases 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
230000003211 malignant effect Effects 0.000 description 4
238000013508 migration Methods 0.000 description 4
230000002611 ovarian Effects 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
231100000241 scar Toxicity 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
210000002784 stomach Anatomy 0.000 description 4
150000008163 sugars Chemical class 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
238000004448 titration Methods 0.000 description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 4
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
108010006654 Bleomycin Proteins 0.000 description 3
238000010599 BrdU assay Methods 0.000 description 3
RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
206010012689 Diabetic retinopathy Diseases 0.000 description 3
240000006497 Dianthus caryophyllus Species 0.000 description 3
235000009355 Dianthus caryophyllus Nutrition 0.000 description 3
238000012286 ELISA Assay Methods 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 3
101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 3
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
208000032612 Glial tumor Diseases 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
208000017604 Hodgkin disease Diseases 0.000 description 3
208000010747 Hodgkins lymphoma Diseases 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
208000009433 Moyamoya Disease Diseases 0.000 description 3
201000010133 Oligodendroglioma Diseases 0.000 description 3
239000004743 Polypropylene Substances 0.000 description 3
102000052575 Proto-Oncogene Human genes 0.000 description 3
108700020978 Proto-Oncogene Proteins 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
208000000453 Skin Neoplasms Diseases 0.000 description 3
208000005718 Stomach Neoplasms Diseases 0.000 description 3
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
210000001789 adipocyte Anatomy 0.000 description 3
206010002224 anaplastic astrocytoma Diseases 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000035578 autophosphorylation Effects 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
229960001561 bleomycin Drugs 0.000 description 3
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 3
230000008499 blood brain barrier function Effects 0.000 description 3
210000001218 blood-brain barrier Anatomy 0.000 description 3
229910000019 calcium carbonate Inorganic materials 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
235000011010 calcium phosphates Nutrition 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000022131 cell cycle Effects 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
230000003833 cell viability Effects 0.000 description 3
230000036755 cellular response Effects 0.000 description 3
108700010039 chimeric receptor Proteins 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
230000002596 correlated effect Effects 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
230000007783 downstream signaling Effects 0.000 description 3
239000008298 dragée Substances 0.000 description 3
235000013861 fat-free Nutrition 0.000 description 3
229960002949 fluorouracil Drugs 0.000 description 3
206010017758 gastric cancer Diseases 0.000 description 3
210000003128 head Anatomy 0.000 description 3
210000002216 heart Anatomy 0.000 description 3
DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
229960000681 leflunomide Drugs 0.000 description 3
208000002780 macular degeneration Diseases 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
206010027191 meningioma Diseases 0.000 description 3
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
230000005012 migration Effects 0.000 description 3
208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
231100000590 oncogenic Toxicity 0.000 description 3
230000002246 oncogenic effect Effects 0.000 description 3
229940045681 other alkylating agent in atc Drugs 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000008188 pellet Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
229920001155 polypropylene Polymers 0.000 description 3
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 3
229960000624 procarbazine Drugs 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000012552 review Methods 0.000 description 3
210000000329 smooth muscle myocyte Anatomy 0.000 description 3
239000002904 solvent Substances 0.000 description 3
206010041823 squamous cell carcinoma Diseases 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
238000007619 statistical method Methods 0.000 description 3
229940124530 sulfonamide Drugs 0.000 description 3
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 3
238000012353 t test Methods 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
230000004862 vasculogenesis Effects 0.000 description 3
229960004528 vincristine Drugs 0.000 description 3
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical group CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 2
HLEQYKBKNSCMBX-UHFFFAOYSA-N 2-(ethoxymethylidene)-3-oxo-n-pyridin-2-ylbutanamide Chemical compound CCOC=C(C(C)=O)C(=O)NC1=CC=CC=N1 HLEQYKBKNSCMBX-UHFFFAOYSA-N 0.000 description 2
KVUYXCNMWQYFQI-UHFFFAOYSA-N 2-(ethoxymethylidene)-3-oxobutanamide Chemical class CCOC=C(C(C)=O)C(N)=O KVUYXCNMWQYFQI-UHFFFAOYSA-N 0.000 description 2
MDYVPTFAVLGYKE-UHFFFAOYSA-N 3,5-dimethyl-n-[3-methyl-4-(trifluoromethyl)phenyl]-1h-pyrazole-4-carboxamide Chemical compound CC1=NNC(C)=C1C(=O)NC1=CC=C(C(F)(F)F)C(C)=C1 MDYVPTFAVLGYKE-UHFFFAOYSA-N 0.000 description 2
UVAATUSSWANHEW-UHFFFAOYSA-N 3,5-dimethyl-n-[4-(trifluoromethylsulfonyl)phenyl]-1,2-oxazole-4-carboxamide Chemical compound CC1=NOC(C)=C1C(=O)NC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 UVAATUSSWANHEW-UHFFFAOYSA-N 0.000 description 2
LUDAOCYKWHUGMO-UHFFFAOYSA-N 3,5-dimethyl-n-[4-(trifluoromethylsulfonyl)phenyl]-1h-pyrazole-4-carboxamide Chemical compound CC1=NNC(C)=C1C(=O)NC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 LUDAOCYKWHUGMO-UHFFFAOYSA-N 0.000 description 2
SZMOPOSBYUHMKU-UHFFFAOYSA-N 3-(2-chlorophenyl)-5-cyclopropyl-n-[3-methyl-4-(trifluoromethyl)phenyl]-1h-pyrazole-4-carboxamide Chemical compound C1=C(C(F)(F)F)C(C)=CC(NC(=O)C2=C(NN=C2C2CC2)C=2C(=CC=CC=2)Cl)=C1 SZMOPOSBYUHMKU-UHFFFAOYSA-N 0.000 description 2
JAICZHZPEAVVJU-UHFFFAOYSA-N 3-(2-chlorophenyl)-5-methyl-n-[4-(trifluoromethylsulfonyl)phenyl]-1h-pyrazole-4-carboxamide Chemical compound CC1=NNC(C=2C(=CC=CC=2)Cl)=C1C(=O)NC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 JAICZHZPEAVVJU-UHFFFAOYSA-N 0.000 description 2
BAUNPFCCLLCVPQ-UHFFFAOYSA-N 3-[4-[[3-methyl-4-(trifluoromethyl)phenyl]carbamoyl]-1,2-oxazol-3-yl]propanoic acid Chemical compound C1=C(C(F)(F)F)C(C)=CC(NC(=O)C=2C(=NOC=2)CCC(O)=O)=C1 BAUNPFCCLLCVPQ-UHFFFAOYSA-N 0.000 description 2
WNATUMUOBADEAD-UHFFFAOYSA-N 3-[4-[[3-methyl-4-(trifluoromethyl)phenyl]carbamoyl]-1h-pyrazol-5-yl]propanoic acid Chemical compound C1=C(C(F)(F)F)C(C)=CC(NC(=O)C=2C(=NNC=2)CCC(O)=O)=C1 WNATUMUOBADEAD-UHFFFAOYSA-N 0.000 description 2
KDLIYDFUZAMICZ-UHFFFAOYSA-N 3-[4-[[4-(trifluoromethylsulfonyl)phenyl]carbamoyl]-1,2-oxazol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=NOC=C1C(=O)NC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 KDLIYDFUZAMICZ-UHFFFAOYSA-N 0.000 description 2
LAYKVEGEKKAIMJ-UHFFFAOYSA-N 3-[4-[[4-(trifluoromethylsulfonyl)phenyl]carbamoyl]-1h-pyrazol-5-yl]propanoic acid Chemical compound OC(=O)CCC1=NNC=C1C(=O)NC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 LAYKVEGEKKAIMJ-UHFFFAOYSA-N 0.000 description 2
PCDWFBFHIIKIPM-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-2-sulfonic acid Chemical compound C1=CC=C2N(CC)C(S(O)(=O)=O)SC2=C1 PCDWFBFHIIKIPM-UHFFFAOYSA-N 0.000 description 2
YBLSBWHFPXDRHC-UHFFFAOYSA-N 3-methyl-1,2-oxazole-4-carboxylic acid Chemical compound CC1=NOC=C1C(O)=O YBLSBWHFPXDRHC-UHFFFAOYSA-N 0.000 description 2
MUSIFRYVOVSNMY-UHFFFAOYSA-N 4h-1,3-benzodioxin-6-amine Chemical group O1COCC2=CC(N)=CC=C21 MUSIFRYVOVSNMY-UHFFFAOYSA-N 0.000 description 2
GETUHHNATFDEKH-UHFFFAOYSA-N 5-(2-chlorophenyl)-3-methyl-n-[3-methyl-4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide Chemical compound CC1=NOC(C=2C(=CC=CC=2)Cl)=C1C(=O)NC1=CC=C(C(F)(F)F)C(C)=C1 GETUHHNATFDEKH-UHFFFAOYSA-N 0.000 description 2
FQQQWOMGEVCFJO-UHFFFAOYSA-N 5-(2-chlorophenyl)-3-methyl-n-[4-(trifluoromethylsulfonyl)phenyl]-1,2-oxazole-4-carboxamide Chemical compound CC1=NOC(C=2C(=CC=CC=2)Cl)=C1C(=O)NC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 FQQQWOMGEVCFJO-UHFFFAOYSA-N 0.000 description 2
JOQWAJNWDBTRMY-UHFFFAOYSA-N 5-methyl-n-[4-(trifluoromethyl)phenyl]-1h-pyrazole-4-carboxamide Chemical compound CC1=NNC=C1C(=O)NC1=CC=C(C(F)(F)F)C=C1 JOQWAJNWDBTRMY-UHFFFAOYSA-N 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
208000006332 Choriocarcinoma Diseases 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
206010014967 Ependymoma Diseases 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
102100028071 Fibroblast growth factor 7 Human genes 0.000 description 2
102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 2
101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 2
102000009465 Growth Factor Receptors Human genes 0.000 description 2
108010009202 Growth Factor Receptors Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
102100039137 Insulin receptor-related protein Human genes 0.000 description 2
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
206010064912 Malignant transformation Diseases 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
208000000172 Medulloblastoma Diseases 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
101100445397 Mus musculus Ephb6 gene Proteins 0.000 description 2
101100268066 Mus musculus Zap70 gene Proteins 0.000 description 2
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
206010029113 Neovascularisation Diseases 0.000 description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
208000022873 Ocular disease Diseases 0.000 description 2
102000043276 Oncogene Human genes 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229930012538 Paclitaxel Natural products 0.000 description 2
241000609499 Palicourea Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
108060006706 SRC Proteins 0.000 description 2
102000001332 SRC Human genes 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
208000024313 Testicular Neoplasms Diseases 0.000 description 2
206010057644 Testis cancer Diseases 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
206010064390 Tumour invasion Diseases 0.000 description 2
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
210000001015 abdomen Anatomy 0.000 description 2
210000003815 abdominal wall Anatomy 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
GCPWJFKTWGFEHH-UHFFFAOYSA-N acetoacetamide Chemical compound CC(=O)CC(N)=O GCPWJFKTWGFEHH-UHFFFAOYSA-N 0.000 description 2
150000004729 acetoacetic acid derivatives Chemical class 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
108091005764 adaptor proteins Proteins 0.000 description 2
102000035181 adaptor proteins Human genes 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
210000001815 ascending colon Anatomy 0.000 description 2
210000002469 basement membrane Anatomy 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
230000003851 biochemical process Effects 0.000 description 2
201000001531 bladder carcinoma Diseases 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000010322 bone marrow transplantation Methods 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000003560 cancer drug Substances 0.000 description 2
230000009400 cancer invasion Effects 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
230000032823 cell division Effects 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000030570 cellular localization Effects 0.000 description 2
230000007541 cellular toxicity Effects 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
210000000038 chest Anatomy 0.000 description 2
201000011024 colonic benign neoplasm Diseases 0.000 description 2
239000000470 constituent Substances 0.000 description 2
230000006552 constitutive activation Effects 0.000 description 2
238000011109 contamination Methods 0.000 description 2
229940097362 cyclodextrins Drugs 0.000 description 2
MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
150000001945 cysteines Chemical class 0.000 description 2
229960000684 cytarabine Drugs 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
229960000975 daunorubicin Drugs 0.000 description 2
230000034994 death Effects 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
229910000397 disodium phosphate Inorganic materials 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
229960004679 doxorubicin Drugs 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
230000013020 embryo development Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
OEYUQMLODPIMSE-UHFFFAOYSA-N ethyl 3-(2-chlorophenyl)prop-2-ynoate Chemical group CCOC(=O)C#CC1=CC=CC=C1Cl OEYUQMLODPIMSE-UHFFFAOYSA-N 0.000 description 2
LFSVADABIDBSBV-UHFFFAOYSA-N ethyl 3-cyclopropyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1CC1 LFSVADABIDBSBV-UHFFFAOYSA-N 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
208000037824 growth disorder Diseases 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
208000014829 head and neck neoplasm Diseases 0.000 description 2
230000036541 health Effects 0.000 description 2
201000002222 hemangioblastoma Diseases 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
238000007489 histopathology method Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
108010054372 insulin receptor-related receptor Proteins 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000007917 intracranial administration Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000012948 isocyanate Substances 0.000 description 2
150000002513 isocyanates Chemical class 0.000 description 2
229960002725 isoflurane Drugs 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
229940015418 ketaset Drugs 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
108020001756 ligand binding domains Proteins 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
230000001926 lymphatic effect Effects 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000036212 malign transformation Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229960001428 mercaptopurine Drugs 0.000 description 2
208000030159 metabolic disease Diseases 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
230000002297 mitogenic effect Effects 0.000 description 2
125000002950 monocyclic group Chemical group 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 2
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical class C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
CNQRUWUTTPVLOW-UHFFFAOYSA-N nitromethylcyclopropane Chemical group [O-][N+](=O)CC1CC1 CNQRUWUTTPVLOW-UHFFFAOYSA-N 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
238000011580 nude mouse model Methods 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
230000033667 organ regeneration Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229960001592 paclitaxel Drugs 0.000 description 2
230000036407 pain Effects 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
230000000865 phosphorylative effect Effects 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
230000002980 postoperative effect Effects 0.000 description 2
FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
229960004618 prednisone Drugs 0.000 description 2
238000012545 processing Methods 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
210000001525 retina Anatomy 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
229940069575 rompun Drugs 0.000 description 2
235000004400 serine Nutrition 0.000 description 2
230000007781 signaling event Effects 0.000 description 2
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
229940048086 sodium pyrophosphate Drugs 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
241000894007 species Species 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
230000007480 spreading Effects 0.000 description 2
238000003892 spreading Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
210000002536 stromal cell Anatomy 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
150000003456 sulfonamides Chemical class 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
240000003177 tenweeks stock Species 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
201000003120 testicular cancer Diseases 0.000 description 2
235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
229960001196 thiotepa Drugs 0.000 description 2
235000008521 threonine Nutrition 0.000 description 2
MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 2
229960003087 tioguanine Drugs 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
229960001005 tuberculin Drugs 0.000 description 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
150000003668 tyrosines Chemical class 0.000 description 2
210000003932 urinary bladder Anatomy 0.000 description 2
208000010570 urinary bladder carcinoma Diseases 0.000 description 2
230000000982 vasogenic effect Effects 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
230000035899 viability Effects 0.000 description 2
229960003048 vinblastine Drugs 0.000 description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
XGNXYCFREOZBOL-UHFFFAOYSA-N 1,3-benzodioxol-5-amine Chemical group NC1=CC=C2OCOC2=C1 XGNXYCFREOZBOL-UHFFFAOYSA-N 0.000 description 1
GWEHVDNNLFDJLR-UHFFFAOYSA-N 1,3-diphenylurea Chemical compound C=1C=CC=CC=1NC(=O)NC1=CC=CC=C1 GWEHVDNNLFDJLR-UHFFFAOYSA-N 0.000 description 1
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
LOTZEUSHKCAQNQ-UHFFFAOYSA-N 2,2,5-trimethyl-1,3-dioxin-4-one Chemical compound CC1=COC(C)(C)OC1=O LOTZEUSHKCAQNQ-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
MPYGFFPGJMGVSW-UHFFFAOYSA-N 3,5-dimethyl-1,2-oxazole-4-carbonyl chloride Chemical compound CC1=NOC(C)=C1C(Cl)=O MPYGFFPGJMGVSW-UHFFFAOYSA-N 0.000 description 1
CUVPFGWHGVKLSA-UHFFFAOYSA-N 3,5-dimethyl-n-[3-methyl-4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide Chemical compound CC1=NOC(C)=C1C(=O)NC1=CC=C(C(F)(F)F)C(C)=C1 CUVPFGWHGVKLSA-UHFFFAOYSA-N 0.000 description 1
GWRGWOPIIUGDPE-UHFFFAOYSA-N 3,5-dimethyl-n-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide Chemical compound CC1=NOC(C)=C1C(=O)NC1=CC=C(C(F)(F)F)C=C1 GWRGWOPIIUGDPE-UHFFFAOYSA-N 0.000 description 1
DQADJOTVQLRCCH-UHFFFAOYSA-N 3,5-dimethyl-n-[4-(trifluoromethyl)phenyl]-1h-pyrazole-4-carboxamide Chemical compound CC1=NNC(C)=C1C(=O)NC1=CC=C(C(F)(F)F)C=C1 DQADJOTVQLRCCH-UHFFFAOYSA-N 0.000 description 1
RYCSNJCJOVQGBC-UHFFFAOYSA-N 3-(1-cyclopropyl-2h-pyridin-4-yl)-1h-quinolin-2-one Chemical class O=C1NC2=CC=CC=C2C=C1C(C=C1)=CCN1C1CC1 RYCSNJCJOVQGBC-UHFFFAOYSA-N 0.000 description 1
OFMPUQCATJAXCF-UHFFFAOYSA-N 3-(2-chlorophenyl)-5-cyclopropyl-n-[3-methyl-4-(trifluoromethylsulfonyl)phenyl]-1h-pyrazole-4-carboxamide Chemical compound C1=C(S(=O)(=O)C(F)(F)F)C(C)=CC(NC(=O)C2=C(NN=C2C2CC2)C=2C(=CC=CC=2)Cl)=C1 OFMPUQCATJAXCF-UHFFFAOYSA-N 0.000 description 1
YKXNERUIAJDQKB-UHFFFAOYSA-N 3-(2-chlorophenyl)-5-cyclopropyl-n-[4-(trifluoromethylsulfonyl)phenyl]-1h-pyrazole-4-carboxamide Chemical compound C1=CC(S(=O)(=O)C(F)(F)F)=CC=C1NC(=O)C1=C(C=2C(=CC=CC=2)Cl)NN=C1C1CC1 YKXNERUIAJDQKB-UHFFFAOYSA-N 0.000 description 1
HDOQTVYBINHQQG-UHFFFAOYSA-N 3-(2-chlorophenyl)-5-methyl-n-[4-(trifluoromethyl)phenyl]-1h-pyrazole-4-carboxamide Chemical compound CC1=NNC(C=2C(=CC=CC=2)Cl)=C1C(=O)NC1=CC=C(C(F)(F)F)C=C1 HDOQTVYBINHQQG-UHFFFAOYSA-N 0.000 description 1
BXRKVJRWUYFZEZ-UHFFFAOYSA-N 3-[4-[[4-(trifluoromethyl)phenyl]carbamoyl]-1,2-oxazol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=NOC=C1C(=O)NC1=CC=C(C(F)(F)F)C=C1 BXRKVJRWUYFZEZ-UHFFFAOYSA-N 0.000 description 1
XUGVKTRQPIJFMA-UHFFFAOYSA-N 3-[4-[[4-(trifluoromethyl)phenyl]carbamoyl]-1h-pyrazol-5-yl]propanoic acid Chemical compound OC(=O)CCC1=NNC=C1C(=O)NC1=CC=C(C(F)(F)F)C=C1 XUGVKTRQPIJFMA-UHFFFAOYSA-N 0.000 description 1
RHGFJMFMHCESJV-UHFFFAOYSA-N 3-cyclopropyl-n-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1NC(=O)C1=CON=C1C1CC1 RHGFJMFMHCESJV-UHFFFAOYSA-N 0.000 description 1
ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
HQFLTUZKIRYQSP-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-6-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2N(CC)CSC2=C1 HQFLTUZKIRYQSP-UHFFFAOYSA-N 0.000 description 1
CUMCMYMKECWGHO-UHFFFAOYSA-N 3-methyl-1,2-oxazole Chemical compound CC=1C=CON=1 CUMCMYMKECWGHO-UHFFFAOYSA-N 0.000 description 1
AVSLCGYMISJJBT-UHFFFAOYSA-N 3-methyl-1,2-oxazole-4-carboxamide Chemical compound CC1=NOC=C1C(N)=O AVSLCGYMISJJBT-UHFFFAOYSA-N 0.000 description 1
OKNMHNHQFDCVHW-UHFFFAOYSA-N 3-methyl-2h-1,3-thiazole-4-carboxylic acid Chemical group CN1CSC=C1C(O)=O OKNMHNHQFDCVHW-UHFFFAOYSA-N 0.000 description 1
YTMVUFIFISNHDB-UHFFFAOYSA-N 3-methyl-4-(trifluoromethyl)aniline Chemical group CC1=CC(N)=CC=C1C(F)(F)F YTMVUFIFISNHDB-UHFFFAOYSA-N 0.000 description 1
BPINZFULXIZOFY-UHFFFAOYSA-N 3-methyl-n-[3-methyl-4-(trifluoromethyl)phenyl]-2h-1,3-thiazole-4-carboxamide Chemical compound CN1CSC=C1C(=O)NC1=CC=C(C(F)(F)F)C(C)=C1 BPINZFULXIZOFY-UHFFFAOYSA-N 0.000 description 1
BNPSLPVRKIZOGX-UHFFFAOYSA-N 3-methyl-n-[4-(trifluoromethyl)phenyl]-2h-1,3-thiazole-4-carboxamide Chemical compound CN1CSC=C1C(=O)NC1=CC=C(C(F)(F)F)C=C1 BNPSLPVRKIZOGX-UHFFFAOYSA-N 0.000 description 1
DNMHOHTUCGATHZ-UHFFFAOYSA-N 3-methyl-n-[4-(trifluoromethylsulfonyl)phenyl]-2h-1,3-thiazole-4-carboxamide Chemical compound CN1CSC=C1C(=O)NC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 DNMHOHTUCGATHZ-UHFFFAOYSA-N 0.000 description 1
GNVFCXUZQGCXPB-UHFFFAOYSA-N 4-(trifluoromethylsulfonyl)aniline Chemical compound NC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 GNVFCXUZQGCXPB-UHFFFAOYSA-N 0.000 description 1
125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
FBEOYGLZXHELIW-UHFFFAOYSA-N 5-(2-chlorophenyl)-3-cyclopropyl-n-[4-(trifluoromethylsulfonyl)phenyl]-1,2-oxazole-4-carboxamide Chemical compound C1=CC(S(=O)(=O)C(F)(F)F)=CC=C1NC(=O)C1=C(C=2C(=CC=CC=2)Cl)ON=C1C1CC1 FBEOYGLZXHELIW-UHFFFAOYSA-N 0.000 description 1
HCTBDTJKBMXHAR-UHFFFAOYSA-N 5-(2-chlorophenyl)-3-methyl-n-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide Chemical compound CC1=NOC(C=2C(=CC=CC=2)Cl)=C1C(=O)NC1=CC=C(C(F)(F)F)C=C1 HCTBDTJKBMXHAR-UHFFFAOYSA-N 0.000 description 1
IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
ZYUKYPJNGPUSFD-UHFFFAOYSA-N 5-cyclopropyl-n-[4-(trifluoromethyl)phenyl]-1h-pyrazole-4-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1NC(=O)C1=CNN=C1C1CC1 ZYUKYPJNGPUSFD-UHFFFAOYSA-N 0.000 description 1
BXDUAHVCZKJBLX-UHFFFAOYSA-N 5-methyl-n'-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carbohydrazide Chemical compound O1N=CC(C(=O)NNC=2C=CC(=CC=2)C(F)(F)F)=C1C BXDUAHVCZKJBLX-UHFFFAOYSA-N 0.000 description 1
CTAQUNHHSNQBCU-UHFFFAOYSA-N 5-methyl-n-[3-methyl-4-(trifluoromethyl)phenyl]-1h-pyrazole-4-carboxamide Chemical compound CC1=NNC=C1C(=O)NC1=CC=C(C(F)(F)F)C(C)=C1 CTAQUNHHSNQBCU-UHFFFAOYSA-N 0.000 description 1
YROKSDGXNKDUHO-UHFFFAOYSA-N 5-methyl-n-[3-methyl-4-(trifluoromethyl)phenyl]-1h-pyrazole-4-carboxamide;5-methyl-n-[4-(trifluoromethylsulfonyl)phenyl]-1h-pyrazole-4-carboxamide Chemical compound N1N=CC(C(=O)NC=2C=C(C)C(=CC=2)C(F)(F)F)=C1C.N1N=CC(C(=O)NC=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=C1C YROKSDGXNKDUHO-UHFFFAOYSA-N 0.000 description 1
SFVAQWDAFROERY-UHFFFAOYSA-N 5-methyl-n-[4-(trifluoromethylsulfonyl)phenyl]-1h-pyrazole-4-carboxamide Chemical compound CC1=NNC=C1C(=O)NC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 SFVAQWDAFROERY-UHFFFAOYSA-N 0.000 description 1
WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical class OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
206010048964 Carotid artery occlusion Diseases 0.000 description 1
206010007687 Carotid artery stenosis Diseases 0.000 description 1
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010008723 Chondrodystrophy Diseases 0.000 description 1
206010063209 Chronic allograft nephropathy Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
206010062344 Congenital musculoskeletal anomaly Diseases 0.000 description 1
AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
229940122029 DNA synthesis inhibitor Drugs 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
208000012239 Developmental disease Diseases 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
206010013883 Dwarfism Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000032027 Essential Thrombocythemia Diseases 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
102000003956 Fibroblast growth factor 8 Human genes 0.000 description 1
102100037680 Fibroblast growth factor 8 Human genes 0.000 description 1
102100037665 Fibroblast growth factor 9 Human genes 0.000 description 1
102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
206010061968 Gastric neoplasm Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
206010019851 Hepatotoxicity Diseases 0.000 description 1
101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 description 1
101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
101001060265 Homo sapiens Fibroblast growth factor 6 Proteins 0.000 description 1
101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 1
101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 description 1
101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 description 1
101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
206010022773 Intracranial pressure increased Diseases 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
208000007433 Lymphatic Metastasis Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
230000027311 M phase Effects 0.000 description 1
108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
206010027459 Metastases to lymph nodes Diseases 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
201000010927 Mucositis Diseases 0.000 description 1
208000034486 Multi-organ failure Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 1
208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
101150038994 PDGFRA gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000609816 Pantholops hodgsonii Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
241000220317 Rosa Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
208000021712 Soft tissue sarcoma Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
241000011102 Thera Species 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
208000033781 Thyroid carcinoma Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
FYGNJYLXDRROPN-UHFFFAOYSA-N [2-(4-phenylmethoxyphenyl)-1,3-thiazol-4-yl]methanamine Chemical group NCC1=CSC(C=2C=CC(OCC=3C=CC=CC=3)=CC=2)=N1 FYGNJYLXDRROPN-UHFFFAOYSA-N 0.000 description 1
USDJGQLNFPZEON-UHFFFAOYSA-N [[4,6-bis(hydroxymethylamino)-1,3,5-triazin-2-yl]amino]methanol Chemical compound OCNC1=NC(NCO)=NC(NCO)=N1 USDJGQLNFPZEON-UHFFFAOYSA-N 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
208000008919 achondroplasia Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000001780 adrenocortical effect Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001299 aldehydes Chemical group 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229960000473 altretamine Drugs 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
229960003437 aminoglutethimide Drugs 0.000 description 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000001741 anti-phlogistic effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000003356 anti-rheumatic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
108010060350 arginyl-arginyl-leucyl-isoleucyl-glutamyl-aspartyl-alanyl-glutamyl-tyrosyl-alanyl-alanyl-arginyl-glycine Proteins 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
150000001541 aziridines Chemical class 0.000 description 1
239000002585 base Substances 0.000 description 1
208000021592 benign granular cell tumor Diseases 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229950005567 benzodepa Drugs 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
229940108502 bicnu Drugs 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000000227 bioadhesive Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
238000012925 biological evaluation Methods 0.000 description 1
230000003592 biomimetic effect Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 description 1
229950010231 brequinar Drugs 0.000 description 1
239000012267 brine Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
230000002252 carbamoylating effect Effects 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
229960002115 carboquone Drugs 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
208000006170 carotid stenosis Diseases 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
208000015100 cartilage disease Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
239000008004 cell lysis buffer Substances 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000004715 cellular signal transduction Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000004720 cerebrum Anatomy 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000012829 chemotherapy agent Substances 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
201000010989 colorectal carcinoma Diseases 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
210000004246 corpus luteum Anatomy 0.000 description 1
210000003792 cranial nerve Anatomy 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000002498 deadly effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
229960000935 dehydrated alcohol Drugs 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
229960000452 diethylstilbestrol Drugs 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000371 dose-limiting toxicity Toxicity 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000008472 epithelial growth Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960001842 estramustine Drugs 0.000 description 1
FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
AEWHICNMVQOWJE-UHFFFAOYSA-N ethyl 3-methyl-1,2-oxazole-4-carboxylate Chemical compound CCOC(=O)C1=CON=C1C AEWHICNMVQOWJE-UHFFFAOYSA-N 0.000 description 1
FCJJZKCJURDYNF-UHFFFAOYSA-N ethyl but-2-ynoate Chemical group CCOC(=O)C#CC FCJJZKCJURDYNF-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229940047127 fiore Drugs 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
150000002224 folic acids Chemical class 0.000 description 1
229960004783 fotemustine Drugs 0.000 description 1
YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
208000010749 gastric carcinoma Diseases 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
230000002518 glial effect Effects 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000003324 growth hormone secretagogue Substances 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
230000004730 hepatocarcinogenesis Effects 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
230000007686 hepatotoxicity Effects 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
231100000171 higher toxicity Toxicity 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
102000044162 human IGF1 Human genes 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
229960001330 hydroxycarbamide Drugs 0.000 description 1
229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000000521 hyperimmunizing effect Effects 0.000 description 1
201000010072 hypochondroplasia Diseases 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
229950008097 improsulfan Drugs 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
230000007794 irritation Effects 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
201000000564 macroglobulinemia Diseases 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
DMVAIJCMWPNOKV-UHFFFAOYSA-N methyl 3-(2-chlorophenyl)-3-oxopropanoate Chemical group COC(=O)CC(=O)C1=CC=CC=C1Cl DMVAIJCMWPNOKV-UHFFFAOYSA-N 0.000 description 1
RIJWDPRXCXJDPK-UHFFFAOYSA-N methyl 3-cyclopropyl-3-oxopropanoate Chemical compound COC(=O)CC(=O)C1CC1 RIJWDPRXCXJDPK-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229950009847 meturedepa Drugs 0.000 description 1
QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
229960000350 mitotane Drugs 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
231100001228 moderately toxic Toxicity 0.000 description 1
HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
230000004899 motility Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
201000005962 mycosis fungoides Diseases 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
201000004130 myoblastoma Diseases 0.000 description 1
LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
FRZJZRVZZNTMAW-UHFFFAOYSA-N n,n-diethyl-3-(hydroxymethyl)benzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(CO)=C1 FRZJZRVZZNTMAW-UHFFFAOYSA-N 0.000 description 1
SLFVYFOEHHLHDW-UHFFFAOYSA-N n-(trifluoromethyl)aniline Chemical compound FC(F)(F)NC1=CC=CC=C1 SLFVYFOEHHLHDW-UHFFFAOYSA-N 0.000 description 1
239000002088 nanocapsule Substances 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
208000025402 neoplasm of esophagus Diseases 0.000 description 1
201000009925 nephrosclerosis Diseases 0.000 description 1
230000007694 nephrotoxicity Effects 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229960001420 nimustine Drugs 0.000 description 1
VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
108091008819 oncoproteins Proteins 0.000 description 1
230000004768 organ dysfunction Effects 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
150000002905 orthoesters Chemical class 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000035515 penetration Effects 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
210000004560 pineal gland Anatomy 0.000 description 1
NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
229950001100 piposulfan Drugs 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
210000001883 posterior pituitary gland Anatomy 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229960004694 prednimustine Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
201000005825 prostate adenocarcinoma Diseases 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
230000007047 pulmonary toxicity Effects 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
125000004076 pyridyl group Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
229960002185 ranimustine Drugs 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
102220226043 rs1064794935 Human genes 0.000 description 1
102220232643 rs1064794935 Human genes 0.000 description 1
102200082402 rs751610198 Human genes 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
208000011581 secondary neoplasm Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
150000003346 selenoethers Chemical class 0.000 description 1
150000003355 serines Chemical class 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
125000005504 styryl group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
210000001994 temporal artery Anatomy 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
KHGJYGFMJDVIRR-UHFFFAOYSA-N tert-butyl 7-nitrononanoate Chemical group CCC([N+]([O-])=O)CCCCCC(=O)OC(C)(C)C KHGJYGFMJDVIRR-UHFFFAOYSA-N 0.000 description 1
229960001712 testosterone propionate Drugs 0.000 description 1
201000003896 thanatophoric dysplasia Diseases 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
150000003588 threonines Chemical class 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
208000013077 thyroid gland carcinoma Diseases 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
229950001353 tretamine Drugs 0.000 description 1
150000003918 triazines Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
230000004222 uncontrolled growth Effects 0.000 description 1
229960001055 uracil mustard Drugs 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
229950006929 uredepa Drugs 0.000 description 1
SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000002699 waste material Substances 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1
238000002689 xenotransplantation Methods 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1